Use of subcutaneous epinephrine in addition to standard first-line treatment with short-acting β2-agonist and systemic steroids in children and adolescents with an acute severe asthma exacerbation: a systematic review of randomised controlled trials

The authors aimed to evaluate the safety and efficacy of subcutaneous epinephrine as an adjunct to standard first-line treatments for acute asthma exacerbations in children and adolescents. Their systematic review identified only one randomized controlled trial involving 43 participants, which found no significant benefits of subcutaneous epinephrine in improving asthma clinical scores, reducing hospitalization rates, or enhancing lung function. The review concluded that the evidence supporting the use of subcutaneous epinephrine in this context is very low.